引用本文
  • 谷晓媛,张为强,陆新元.肝胆肿瘤组织中PD-L1的表达水平及临床病理研究[J].同济大学学报(医学版),2019,30(3):315-320.    [点击复制]
  • GU Xiao-yuan,ZHANG Wei-qiang,LU Xin-yuan.Expression of PD-L1 in hepatobiliary malignant tumor tissues and its relationship with clinicopathological parameters[J].同济大学学报(医学版),2019,30(3):315-320.   [点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 29次   下载 36 本文二维码信息
码上扫一扫!
肝胆肿瘤组织中PD-L1的表达水平及临床病理研究
谷晓媛,张为强,陆新元
0
(上海市静安区市北医院肿瘤科,上海 200443;上海市东方肝胆外科医院病理科,上海 200438)
摘要:
目的 调查肝胆恶性肿瘤组织内程序性死亡受体(programmed cell death 1 ligand 1, PD-L1)的表达情况,并研究HCC中PD-L1的表达与临床病理参数间的关系。方法 选取2018年1月1日—2018年10月31日于东方肝胆外科医院接受手术、由同一病理科医师诊断的行PD-L1免疫组织化学染色的肝胆肿瘤病例,收集临床病理参数、比较分析PD-L1在不同瘤种之间的表达差异;再选取HCC病例,统计分析HCC组织内PD-L1的表达与临床病理参数间的关系。结果 HCC、ICC、cHCC-CCA、肝外胆管癌肿瘤组织内PD-L1的阳性率分别为为21.6%、29.7%、14.3%和6.9%;HCC组织内PD-L1的表达与年龄、性别、AFP阳性、HBsAg阳性、肝硬化有无、肿瘤大小、子灶有无无关。双表型HCC的PD-L1阳性率明显高于其他组织学亚型(P=0.018);PD-L1阳性组的MVI阳性率高于PD-L1阴性组的MVI阳性率(P=0.003);PD-L1阳性组的Ⅲ~Ⅳ级分化比例高于PD-L1阴性组的Ⅲ~Ⅳ级分化比例(P=0.016);PD-L1阳性组的CK-19阳性率高于PD-L1阴性组的CK19阳性率(P=0.035);PD-L1阳性组的T3期比例高于PD-L1阴性组的T3期比例(P=0.004)。结论 HCC组织内PD-L1的表达与组织学亚型、MVI、组织学分级、CK19表达、T分期有关,推测PD-L1的高表达可能与肝脏干/祖细胞有关、未来需要进一步分子生物学实验验证。
关键词:  肝细胞癌  PD-L1  免疫治疗  派姆单抗
DOI:10.16118/j.1008-0392.2019.03.010
投稿时间:2018-12-12
基金项目:国家自然科学基金青年项目(81602603)
Expression of PD-L1 in hepatobiliary malignant tumor tissues and its relationship with clinicopathological parameters
GU Xiao-yuan,ZHANG Wei-qiang,LU Xin-yuan
(Dept. of Oncology, Shanghai Shibei Hospital of Jing’an District, Shanghai 200443, China;Dept. of Pathology, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China)
Abstract:
Objective To investigate the expression of PD-L1 in hepatobiliary malignant tumor tissues, and its relationships with clinicopathological parameters of the tumor. Methods Clinical and pathological data of 434 patients with hepatobiliary malignant tumors, including 347 cases of hepatocellular carcinoma (HCC), 37 cases of intrahepatic cholangiocarcinoma (ICC), 7 cases of combined hepatocellular-cholangiocarcinoma (cHCC-CCA)and 43 case of extrahepatic cholangiocarcinoma, who underwent surgery in Eastern Hepatobiliary Hospital during January 2011 to October 2018 were retrospectively reviewed. The expression of PD-L1 in tumor tissues was detected with immunohistochemical staining. The relationships between PD-L1 expression and clinicopathological parameters of the tumors was analyzed. Results The positive rates of PD-L1 in HCC, ICC, cHCC-CCA and extrahepatic cholangiocarcinoma were 21.6%, 29.7%, 14.3% and 6.9%, respectively. The expression of PD-L1 in HCC tissues was independent of age, gender, AFP, HBsAg, presence or absence of cirrhosis, tumor size and subfocus. The PD-L1 positive rate of DPHCC was significantly higher than that of other histological subtypes (P=0.018). The microvascular invasion (MVI) positive rate (P=0.003), the proportion of pathological stage Ⅲ~Ⅳ (P=0.016), the CK19 positive rate (P=0.035) and the proportion of T3 stage (P=0.004) in patients with positive PD-L1 were significantly higher than those in patients with negative PD-L1. Conclusion The expression of PD-L1 in HCC tissues is related to histological subtypes, MVI, histological grading, CK19 expression and T stage.
Key words:  hepatocellular carcinoma  PD-L1  immunotherapy  pembrolizumab

您是第1422462位访问者
版权所有《同济大学学报(医学版)》编辑部
主管单位:教育部 主办单位:同济大学
地  址: 上海四平路1239号 邮编:200092 电话:021-65980705 E-mail: yxxb@tongji.edu.cn
本系统由北京勤云科技发展有限公司设计